VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy

Bevacizumab, an anti-vascular endothelial growth factor (VEGF-A) antibody, is used in metastatic colorectal carcinoma (CRC) treatment, but responses are unpredictable. Vascular endothelial growth factor is alternatively spliced to form proangiogenic VEGF(165) and antiangiogenic VEGF(165)b. Using iso...

詳細記述

保存先:
書誌詳細
主要な著者: Varey, A H R, Rennel, E S, Qiu, Y, Bevan, H S, Perrin, R M, Raffy, S, Dixon, A R, Paraskeva, C, Zaccheo, O, Hassan, A B, Harper, S J, Bates, D O
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 2008
主題:
Translational Therapeutics
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361696/
https://ncbi.nlm.nih.gov/pubmed/18349829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604308
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料